Related Experiment Video
Updated: Aug 5, 2026
10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
Insulin Encapsulation in a Chitosan-Alginate Matrix and In Vitro Release
Ruth Reyes1, María Luisa Ojeda-Martínez1, Armin Hernández-Gordillo1
1Departamento de Ciencias Naturales y Exactas, Centro Universitario de los Valles, Universidad de Guadalajara, Ameca 46600, Jalisco, Mexico.
Bioengineering (Basel, Switzerland)
|July 28, 2026
Summary
Researchers developed novel chitosan-alginate nanoparticles for improved insulin delivery. These nanoparticles show pH-responsive release, offering a promising alternative to conventional insulin injection methods.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Pharmaceutical Sciences
Background:
- Conventional insulin therapy faces limitations, necessitating alternative delivery systems.
- Recombinant human insulin delivery requires advanced platforms for better patient compliance.
- Chitosan-alginate systems offer potential for controlled drug release applications.
Purpose of the Study:
- To design, synthesize, and characterize chitosan-alginate nanoparticles for insulin encapsulation.
- To evaluate the pH-responsive release behavior of insulin from these nanoparticles.
- To assess the potential of these nanosystems as an alternative insulin delivery strategy.
Main Methods:
- Nanoparticles were prepared using ionic crosslinking with sodium tripolyphosphate (TPP).
- Characterization involved UV-vis spectroscopy, FTIR-ATR, DLS, zeta potential, fluorescence spectroscopy, and SEM.
- In vitro release studies were performed at acidic (pH 4.5) and neutral/basic (pH 7.4) conditions.
Main Results:
- High encapsulation efficiency and positive zeta potential were observed.
- SEM indicated elongated nanoparticle morphology; DLS confirmed nanometric sizes.
- pH-dependent release demonstrated rapid release at pH 4.5 and sustained release at pH 7.4, even after storage.
Conclusions:
- Synthesized chitosan-alginate nanoparticles serve as a biocompatible platform for insulin encapsulation.
- The pH-responsive release profile supports their potential for alternative insulin delivery.
- These nanosystems could enhance therapeutic adherence and accessibility for diabetes management.
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:05Insulin Secretory Vesicles
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...